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Summary Current evidence suggests that epilepsy outcome for people with a learning
disability is poor, with the majority remaining refractory to treatment. There is very
little evidence from randomised controlled trials in this population and despite the
many uncontrolled variables it is suggested that an outcome audit may be one method
of adding to the evidence base.
This audit reports on the outcome for 37 patients with learning disability and re-
fractory epilepsy. All patients were seen for the ﬁrst time before March 2001 and
the mean number of seizures for the sample was 10.4 per month. The exit audit in-
cluded all patients at a date 2 years after their initial visit following a programme
of medication changes. The mean seizure frequency had reduced to 5.9 per month.
Ten patients had become seizure-free and 76% had experienced an improvement in
seizure frequency overall.
A simple questionnaire was administered to carers and relatives at the exit audit
in an attempt to establish an impression of global changes in alertness, assertive-
ness and challenging behaviour following interventions. Sixty-ﬁve percent of patients
were regarded as being more aware and interactive with their surroundings following
medication changes and 49% were reported to be more assertive. Thirty percent pre-
sented with an increase in behaviours regarded as challenging and 22% were reported
to present with less challenging behaviour.
The results of this audit suggest that the outcome for the majority of patients with
learning disability and refractory epilepsy may be better than that has been previously
reported.
© 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
It is recognised that 14—24% of people with a learn-
ing disability are affected by epilepsy.1 Multiple
seizure types are common and it is suggested that
up to three-quarters of patients remain refractory
to treatment.2
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There is little clinical trial data available on peo-
ple with learning disability because of perceived
ethical problems surrounding capacity to consent,
diagnostic difﬁculties, investigative problems and
issues regarding compliance with drug treatment.
Where research evidence is lacking, the audit of
clinical outcomes over a prolonged period remains
one of the few ways of informing clinicians and pro-
viding an evidence base.
Many learning disabled patients remain on old
fashioned treatment regimes and the hypothesis
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was that it was possible to withdraw older anti-
epileptic drugs (AEDs), replacing them with more
modern treatment and that this would lead to
improvements in both epilepsy and quality of life.
This paper reports on the outcome for patients
with learning disability and refractory epilepsy fol-
lowing 2 years of clinical intervention by a commu-
nity learning disability service. The only changes in
the service were the appointment of a consultant
neuropsychiatrist with a special interest in epilepsy
and specialist epilepsy training for two community
learning disability nurses.
Methodology
As most clinicians aim to attain seizure freedom on
one AED, this was considered to be the outcome
standard, accepting that in most clinical trials, a
50% seizure reduction is considered to be a good
outcome. The audit included all adults over the age
of 19 within an established community learning dis-
ability service presenting for ﬁrst consultation at
the outpatient clinic before 1 March 2001.
The following parameters were measured: aver-
age number of seizures per month (over a 3-month
period), type of seizures, number of AEDs and
side-effects of medication.
The changes to AEDs reﬂected normal clinical
practice with no formal protocols followed, but
with the aim to withdraw older preparations replac-
ing them with more modern treatment. Changes to
AEDs were made on an individual basis with consid-
eration of refractoriness of seizures, seizure type,
the presence of potential adverse drug effects and
the ability of the patient to tolerate different drug
formulations or preparations. It is acknowledged
that the AED changes implemented reﬂect the clin-
ical preferences and clinical experience of a single
consultant.
Community learning disability nurses negotiated
detailed care plans for making the recommended
AED changes with care staff and other support
agencies such as day care providers. They also
provided close monitoring of effectiveness and tol-
Figure 1 Questionnaire.
erability providing education and training for care
staff where necessary.
Despite inconclusive evidence to support the
view that behavioural problems are more fre-
quently found in those people with a learning dis-
ability who also have epilepsy,3 the clinical impres-
sion frequently exists that people with a learning
disability who also have epilepsy are more likely to
have behaviour problems fuelled by the belief that
both epilepsy and AEDs may affect behaviour.
As part of the exit audit, a questionnaire was ad-
ministered to carers and relatives after completion
of the 2-year cycle to determine any changes in lev-
els of alertness, assertiveness and challenging be-
haviour (Fig. 1).
The outcome audit reviewed the parameters of
seizure frequency, severity and type and potential
adverse effects of medication at a date 2 years af-
ter the ﬁrst consultation. A global average over the
previous 3 months was used.
Results
Thirty-seven patients were included in the out-
come audit. Details of current seizure frequency
and seizure type had been recorded on a monthly
basis since the ﬁrst visit. Monthly seizure frequency
ranged from 0.5 to 60 with a mean of 10.4 seizures
for the group at the time of the ﬁrst consultation
(Table 1).
After 2 years, the mean monthly seizure fre-
quency had reduced to 5.9. Twenty-eight patients
had experienced a decrease in the frequency of
their seizures (76%). Twenty-one patients (57%)
had a greater than 50% reduction in seizure fre-
quency and of these patients, 10 (27%) had been
seizure-free for at least 6 months. Seven patients
(19%) had an increase in seizure frequency and
in two patients there was no reported change
(Table 1).
Recognised side-effects were reported in 19 pa-
tients (51%) at the ﬁrst consultation with excessive
sedation (nine patients, 24%) the most commonly
reported (Table 2). Side-effects were reported in
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Table 1 Seizure outcome after 2 years.
Outcome parameter (n = 37) Patient numbers
Reduced seizure frequency 28 (76%)
>50% reduction in seizure
frequency
21 (57%)
Seizure-free for at least 6
months
10 (27%)
Seizures unchanged 2 (5%)
Increased seizure frequency 7 (19%)
Mean average seizure frequency
at ﬁrst consultation
10.4 (0.5—60)
Mean average seizure frequency
at end of 2 years
5.9 (0—44)
nine patients (24%) at the exit audit with tremor
being the most commonly reported (six patients,
16%) (Table 2). Twenty-one patients (57%) in the
sample continued to have generalised tonic-clonic
seizures (primary or secondary) as their main
seizure type compared to 30 (81%) at the ﬁrst
consultation.
The results of the questionnaire showed that fol-
lowing changes to AEDs, 24 patients (65%) were re-
garded as being more aware and interactive with
their surroundings. Two patients (5%) were reported
to be less aware and 11 patients (30%) remained
unchanged (Table 3).
Eighteen patients (49%) were regarded as more
assertive following drug changes with 16 (43%)
Table 3 Results of questionnaire.
Statement (n = 37) Increased (4 or 5) Unchanged (3) Decreased (1 or 2)
Awareness and interaction with surroundings
following drug changes
24 (65%) 11 (30%) 2 (5%)
Assertiveness following drug changes 18 (49%) 16 (43%) 3 (8%)
Challenging behaviour following drug changes 11 (30%) 18 (49%) 8 (22%)
Table 4 Outcome of questionnaire in seizure-free patients and those who experienced worsening of seizures.
Outcome parameter Increased
(4 or 5)
Unchanged
(3)
Decreased
(1 or 2)
Awareness/interaction with surroundings in
seizure-free patients (n = 10)
5 (50%) 5 (50%) 0 (0%)
Awareness/interaction with surroundings and
worse seizure frequency (n = 7)
4 (57%) 1 (14%) 2 (29%)
Assertiveness in seizure-free patients (n = 10) 4 (40%) 5 (50%) 1 (10%)
Assertiveness and worse seizure frequency (n = 7) 2 (29%) 4 (57%) 1 (14%)
Challenging behaviour in seizure-free patients (n = 10) 3 (30%) 5 (50%) 2 (20%)
Challenging behaviour and worse seizure frequency (n = 7) 2 (29%) 5 (71%) 0 (0%)
Table 2 Side-effects of medication (some patients
reported more than one side-effect).
Side-effect First
consultation
(19 patients)
Two-year
outcome
(9 patients)
Sedation/drowsiness 9 2
Ataxia/unsteadiness 6 1
Weight gain 2 2
Weight loss 1 2
Tremor 3 6
Behaviour problems 6 4
unchanged and 3 (8%) showing less assertiveness.
Eleven patients (30%) presented with an increase
in behaviours regarded as challenging, 8 patients
(22%) had less challenging behaviour and 18 (49%)
were unchanged (Table 3). The only apparent differ-
ences between the group who became seizure-free
and the group who experienced a worsening of
seizures was that the worsening of seizures ap-
peared to be associated with less awareness and
interaction with surroundings for some patients
(Table 4).
Table 5 shows the AEDs taken at the ﬁrst consulta-
tion compared with the AEDs following medication
changes at the end of the 2 years. Of the eight pa-
tients who withdrew phenytoin, two (25%) became
seizure-free, four (50%) experienced a greater than
50% reduction in seizure frequency and two (25%)
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Table 5 AED changes over audit cycle.
AED Number of
patients at ﬁrst
consultation
Number of
patients after
2 years
Phenytoin 8 0
Primidone 3 0
Carbamazepine 20 2
Sodium valproate 24 28
Topiramate 1 2
Lamotrigine 14 28
Vigabatrin 1 0
Levetiracetam 0 20
Diazepam 2 1
Clobazam 3 0
experienced a worsening of seizures. Almost 90%
showed increased awareness and interaction with
their surroundings following drug withdrawal and
there was no signiﬁcant impact on the levels of chal-
lenging behaviour.
Table 6 Outcome following speciﬁc AED changes.
Outcome parameter Seizure-free >50% seizure reduction Increase in seizures
Following phenytoin withdrawal (n = 8) 2 (25%) 4 (50%) 2 (25%)
Following carbamazepine withdrawal (n = 20) 5 (25%) 7 (35%) 6 (30%)
Patients taking Lamotrigine (n = 28) 6 (21%) 10 (36%) 8 (29%)
Patients taking Levetiracetam (n = 20) 3 (15%) 7 (45%) 6 (30%)
Table 7 Outcome for patients following speciﬁc drug changes.
Outcome parameter Increased
(4 or 5)
Unchanged
(3)
Decreased
(1 or 2)
Awareness and interaction with surroundings following phenytoin
withdrawal (n = 8)
7 (87.5%) 1 (12.5%) 0 (0%)
Assertiveness following phenytoin withdrawal (n = 8) 5 (62.5%) 3 (37.5%) 0 (0%)
Challenging behaviour following phenytoin withdrawal (n = 8) 1 (12.5%) 6 (75%) 1 (12.5%)
Awareness and interaction with surroundings following
carbamazepine withdrawal (n = 20)
13 (65%) 7 (35%) 0 (0%)
Assertiveness following carbamazepine withdrawal (n = 20) 10 (50%) 9 (45%) 1 (5%)
Challenging behaviour following carbamazepine withdrawal
(n = 20)
5 (25%) 9 (45%) 6 (30%)
Awareness and interaction with surroundings following
Lamotrigine initiation (n = 14)
9 (64%) 5 (36%) 0 (0%)
Assertiveness following Lamotrigine initiation (n = 14) 7 (50%) 6 (43%) 1 (7%)
Challenging behaviour following Lamotrigine initiation (n = 14) 4 (29%) 6 (43%) 4 (29%)
Awareness and interaction with surroundings following
Levetiracetam initiation (n = 20)
14 (70%) 4 (20%) 2 (10%)
Assertiveness following Levetiracetam initiation (n = 20) 11 (55%) 7 (35%) 2 (10%)
Challenging behaviour following Levetiracetam initiation (n = 20) 7 (35%) 8 (40%) 5 (25%)
In the group of 20 patients who withdrew carba-
mazepine, 5 (25%) became seizure-free, 9 (45%) ex-
perienced reduced seizure frequency and of these
7 patients (35%) had a greater than 50% reduction
in frequency. In total 70% showed an improvement
following carbamazepine withdrawal (Table 6). In
13 (65%) there was a reported increased awareness
and interaction with surroundings (Table 7).
In the group of 28 patients who were taking
Lamotrigine at the exit audit, 20 (71%) had an im-
provement in seizure frequency, including 6 (21%)
who became seizure-free, and 10 (36%) who had
a greater than 50% seizure reduction (Table 6). Of
the 14 patients started on Lamotrigine, 9 (64%)
were reported to be more aware and interactive
with surroundings (Table 7).
Twenty patients started on the new AED Leve-
tiracetam were still taking this medication at the
2-year exit audit. In this sample, 14 (70%) reported
reduced seizure frequency with 3 patients (15%)
becoming seizure-free and 7 (45%) reporting a
greater than 50% reduction. Six patients reported a
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worsening of seizures (30%) (Table 6). Fourteen
(70%) showed an increase in awareness and inter-
action with their surroundings and 7 (35%) patients
were considered to be more challenging (Table 7).
Discussion
The result of this audit suggests that there is scope
to improve the outcome for those people with a
learning disability who are considered to have re-
fractory epilepsy.
Whilst the numbers are small and there is no ran-
domisation or comparitor group, it is difﬁcult to ig-
nore the fact that there was globally an almost 50%
reduction in seizures for the group as a whole (av-
erage reduction in seizures from 10.4 to 5.9 per
month) and a substantial number of individuals had
become seizure-free over the 2-year period.
There could be an assumption that, at the initial
assessment, side-effects of medication were under-
diagnosed because a number of individuals had little
or no verbal communication. It is therefore hearten-
ing to have observed a 47% reduction in side-effects
over the 2-year period (19 patients at the outset
and 9 after 2 years).
Previously reported poor outcomes for patients
with learning disability compared to the rest
of the epilepsy population,4 may not necessar-
ily be correct. Guidelines for managing epilepsy
in people with learning disability have recently
been published5 with a signiﬁcant emphasis on
the importance of many factors other than med-
ication changes. Nonetheless this audit suggests
that withdrawing older AEDs with more signiﬁcant
side-effects and replacing them with newer AEDs
can result in an improvement in epilepsy (with a re-
duction in seizure frequency) and an improvement
in awareness and assertiveness (with a presumptive
improvement in quality of life).
It is difﬁcult to attribute the improvements seen
in this audit population to AED changes alone or in-
deed to any single factor. There was an assumption
at the outset that the service could not run with-
out signiﬁcant input from the community learning
disability nurses.
It is suggested that improvement was achieved
through a combination of factors including multidis-
ciplinary team working, the appointment of a spe-
cialist with experience in managing epilepsy, the
community-based nature of the service and switch-
ing to more modern AEDs. It is also suggested that
improved outcomes for this population do not nec-
essarily require substantial additional funding since
this service was provided within the existing re-
sources of an established community learning dis-
ability service.
Further research needs to examine the relation-
ship between epilepsy, AEDs, challenging behaviour
and quality of life in people with a learning disabil-
ity. The challenge will be to do this as a prospective
study with an attempt to control as many of the
variables as possible.
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